Annuaire scientifique
Dr Maeva DUFIES
Chercheur Post-Doctorante - Équipe Mécanismes de Résistance aux Thérapies CibléesTel.
Email : [javascript protected email address]
Thèmes de recherche développés
Publications CSM
-
A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma
Montemagno C, Durivault J, Gastaldi C, Dufies M, Vial V, He X, Ambrosetti D, Kamenskaya A, Négrier S, Bernhard J-C, Borchiellini D, Cao Y, Pagès G
mol 21 Feb 2023, 45 -
Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti- angiogenic therapy
Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grépin R, Rioux-Leclercq N, Bernhard J-C, Pagès G, Dufies M
BJU Int 2022 Jan;129(1):80-92 -
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
Hagege A, Saada-Bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, Rousset J, Montemagno C, Doyen J, Pedeutour F, Parola J, Bourget I, Luciano F, Bozec A, Cao Y, Pagès G, Dufies M
Cell Reports Medicine 3(9): 100659 -
Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas
Penco-Campillo M, Molina C, Piris P, Soufi N, Carré M, Pagnuzzi M, Picco V, , Dufies M, Ronco C, Benhida R, Martial S, Pagès G
Cells 11(23), 3933 -
Cancer associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to antiangiogenic therapy
Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grépin R, Rioux-Leclercq N, Bernhard J-C, Pagès G, Dufies M
BJU Int doi: 10.1111/bju.15506. -
Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression
Cooley L S, Rudewicz J, Souleyreau W, Emanuelli A, Alvarez-Arenas A, Clarke K, Falciani F, Dufies M, Lambrechts D, Modave E, Chalopin-Fillot D, Pineau R, Ambrosetti D, Bernhard J-C, Ravaud A, Négrier S, Ferrero J-M, Pagès G, Benzekry S, Nikolsky M, Bikfalvi A
Mol. Cancer 20:136 -
In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study
Montemagno C, Serrano B, Durivault J, Nataf V, Mocquot F, Amblard R, Vial V, Ronco C, Benhida R, Dufies M, Faraggi M, Pagès G
Biochem Biophys Rep 27: 101098 -
Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
Dufies M, Verbiest A, Cooley L S, Ndiaye P D, He W, Nottet N, Souleyreau W, Hagege A, Torrino S, Parola J, Giuliano S, Borchiellini D, Schiappa R, Mograbi B, Zucman-Rossi J, Bensalah K, Ravaud A, Auberger P, Bikfalvi A, Chamorey E, Rioux-Leclercq N, Mazure N M, Beuselinck B, Cao Y, Bernhard J C, Ambrosetti D, Pagès G
Comm Biol 4: 166 -
The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy
Hagege A, Ambrosetti D, Boyer J, Bozec A, Doyen J, Chamorey E, He X, Bourget I, Rousset J, Saada E, Rastoin O, Parola J, Luciano F, Cao Y, Pagès G, Dufies M
Theranostics 11(19): 9571-9586 -
UBTD1 regulates ceramide balance and endolysosomal positioning to coordinate EGFR signaling
Torrino S, Tiroille V, Dolfi B, Dufies M, Hinault C, Bonesso L, Dagnino S, Uhler J, Irondelle M, Gay A S, Fleuriot L, Debayle D, Lacas-Gervais S, Cormont M, Bertero T, Bost F, Gilleron J, Clavel S
Elife 10(e68348): 1-24 -
Co-culture of human fibroblasts, smooth muscle and endothelial cells promotes osteopontin induction in hypoxia
Sadaghianloo N, Contenti J, Dufies M, Parola J, Rouleau M, Lee S, Peyron J-F, Fabbri L, Hassen-Khodja R, Pouyssegur J, Bost F, Jean-Baptiste E, Dardik A, Mazure N M
J Cell Mol Med 24(5): 2931-2941 -
Evidences of a direct relationship between cellular fuel supply and ciliogenesis regulated by hypoxic VDAC1-∆C
Meyenberg Cunha-de Padua M, Fabbri L, Dufies M, Lacas-Gervais S, Contenti J, Voyton C, Fazio S, Irondelle M, Mograbi B, Rouleau M, Sadaghianloo N, Rovini A, Brenner C, Craigen W J, Bourgeais J, Herault O, Bost F, Mazure N M
Cancers 12(11): 3484 -
Experimental models in neovascular age related macular degeneration
Rastoin O, Pagès G, Dufies M
Int J Mol Sci 21: 4627 -
Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients
Dufies M, Fabbri L, Lacas-Gervais S, Gardie B, Gad-Lapiteau S, Parola J, Nottet N, Meyenberg Cunha de Padua M, Contenti J, Borchiellini D, Ferrero J-M, Rioux Leclercq N, Ambrosetti D, Mograbi B, Richard S, Viotti J, Chamorey E, Sadaghianloo N, Rouleau M, Craigen W J, Mari B, Clavel S, Pagès G, Pouyssegur J, Bost F, Mazure N M
Theranostics 10(6): 2696-2713 -
SH3BGRL2, a new down regulated tumor suppressor in clear cell renal cell carcinomas
Dufies M
EBioMedicine 52: 102641 -
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Montemagno C, Hagege A, Borchiellini D, Thamphya B, Rastoin O, Ambrosetti D, Iovanna J, Rioux-Leclercq N, Porta C, Négrier S, Ferrero J-M, Chamorey E, Pagès G, Dufies M
Oncoimmunology 9:1, 1846901 -
Synthesis and biological evaluation of 3-amino-1,2,4-triazole derivatives as potential anticancer compounds
Grytsai O, Valiashko O, Penco-Campillo M, Dufies M, Hagege A, Demange L, Martial S, Pagès G, Ronco C, Benhida R
Bioorg Chem 104: 104271 -
In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer.
Montemagno C , Dumas L, Cavaillès P, Ahmadi M, Bacot S, Debiossat M, Soubies A, Djaïleb L, Leenhardt J, De Leiris N, Dufies M, Pagès G, Hernot S, Devoogdt N, Perret P, Riou L, Fagret D, Ghezzi C, Broisat A
Cancers 11(7). pii: E1039 -
Large expert-curated database for benchmarking document similarity detection in biomedical literature search
Brown P, Relish Consortium, Dufies M, Zhou Y
Database baz085 -
New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments
Dufies M, Grytsai O, Ronco C, Camara O, Ambrosetti D, Hagege A, Parola J, Mateo L, Ayrault M, Giuliano S, Grépin R, Lagarde N, Montes M, Auberger P, Demange L, Benhida R, Pagès G
Theranostics 9(18): 5332–5346 -
PGC-1α inhibits polyamine synthesis to suppress prostate cancer aggressiveness
Kaminski L, Torrino S, Dufies M, Djabari Z, Haider R, Roustan F-R, Jaune E, Laurent K, Nottet N, Michiels J-F, Gesson M, Rocchi S, Mazure N M, Durand M, Tanti J-F, Ambrosetti D, Clavel S, Ben-Sahra I, Bost F
Cancer Res 79(13): 3268-3280 -
Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5
Giuliano S, Dufies M, Ndiaye P D, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero J-M, Mograbi B, Pagès G
Theranostics 9(4): 1181-1199 -
VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
Ndiaye P D, Dufies M, Giuliano S, Douguet L, Grépin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P, Pagès G
Theranostics 9(3): 661-675 -
Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard J C, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero J M, Chamorey E, Blot-Chabaud M, Pagès G
Theranostics 8(9): 2447-2458 -
The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma
Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, Pouyssegur J, Rioux-Leclercq N, Pagès G, Burel-Vandenbos F, Mazure N
PLoS ONE 13(2): e0193477 -
The tyrosine kinase inhibitor Sunitinib targets Vascular Endothelial (VE)-cadherin: a marker of response to antitumoral treatment in metastatic renal cell carcinoma
Polena H, Creuzet J, Dufies M, Sidibé A, Khalil-Mgharbel A, Salomon A, Deroux A, Quesada J-L, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura C, Borchiellini D, Ferrero J-M, Escudier B, Négrier S, Pagès G, Vilgrain I
Br J Cancer 118(9): 1179-1188 -
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley L S, Ambrosetti D, Guyot M, Ndiaye P D, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacques A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero J M, Pagès G
Br J Cancer 117(7): 947-953 -
Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.
Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye P D, Mastri M, Moghrabi W, Cooley L S, Ettaiche M, Chamorey E, Parola J, Vial V, Lupus-Plesu M, Bernhard J C, Ravaud A, Borchiellini D, Ferrero J M, Bikfalvi A, Ebos J M, Khabar K S, Grépin R, Pagès G
Cancer Res 77(5): 1-15 -
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux
Giuliano S, Cormerais Y, Dufies M, Grépin R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S, Mazure N M, Benhida R, Auberger P, Mograbi B, Pagès G
Autophagy 11(10): 1891-1904